patients, Canadian Cardiovascular Society anginal class was improved by 1 class in 86% of EECP-treated patients (95% CI: 82% to 90%). There was, however, a high degree of het- erogeneity among the studies, which lessens confidence in the results of the meta-analysis (Q statistic P=0.008).52 The EECP Consortium reported results from 2289 consecutive patients undergoing EECP therapy at 84 participating centers, includ- ing a subgroup of 175 patients from 7 centers who underwent radionuclide perfusion stress tests before and after therapy.53 Treatment was associated with improved perfusion images and increased exercise duration. Similarly, the International EECP Registry reported improvement of 1 Canadian Cardiovascular Society angina class in 81% of patients immediately after the last EECP treatment.54 Improvements in health-related quality of life have also been reported with EECP, but there is limited evidence with which to determine the duration of the health- related benefits of treatment.55,56 In general, existing data, largely from uncontrolled stud- ies, suggest a benefit from EECP among patients with angina refractory to other therapy.Additional data from well-designed RCTs are needed to better define the role of this therapeutic strategy in patients with SIHD.57 On the basis of this re-exam- ination of the literature, the recommendation about EECP remains unchanged from the 2012 guideline. 5. CAD Revascularization 5.2. Revascularization to Improve Survival: Recommendations See Table 4 for recommendations on CAD revascularization to improve survival and Online Data Supplement 4 for evi- dence supporting the recommendations. 5.6. CABG Versus PCI 5.6.2. CABG Versus Drug-Eluting Stents See Online Data Supplement 5 for additional evidence table. Although the results of 10 observational studies comparing CABG and drug-eluting stent (DES) implantation have been mostofthesestudieshadshortfollow-upperiods (12 to 24 months). 